BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32089217)

  • 1. Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.
    Brunner AM; Steensma DP
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):379-391. PubMed ID: 32089217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
    Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
    Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
    Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
    Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
    Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
    Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
    Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP
    Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splicing factor mutant myelodysplastic syndromes: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
    Nagehan P; Sabbir M; Song J; Mohammad H
    J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Splicing factor mutations in myelodysplastic syndromes].
    Shiozawa Y
    Rinsho Ketsueki; 2018; 59(5):566-573. PubMed ID: 29877248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
    Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
    Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.
    Zhang J; Ali AM; Lieu YK; Liu Z; Gao J; Rabadan R; Raza A; Mukherjee S; Manley JL
    Mol Cell; 2019 Oct; 76(1):82-95.e7. PubMed ID: 31474574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia.
    Figg JW; Barajas JM; Obeng EA
    Curr Opin Hematol; 2021 Mar; 28(2):73-79. PubMed ID: 33492002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.
    Kataoka N; Matsumoto E; Masaki S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
    Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
    Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.